Caren van Roekel

80 Chapter 2 99. Sommer WH, Ceelen F, Garcia-Albeniz X, Paprottka PM, Auernhammer CJ, Armbruster M, et al. Defining predictors for long progression-free survival after radioembolisation of hepatic metastases of neuroendocrine origin. Eur Radiol. 2013;23(11):3094-103. Epub 2013/06/29. 100. Mojtahedi A, Thamake S, Tworowska I, Ranganathan D, Delpassand ES. The value of 68Ga DOTATATE PET/ CT in diagnosis and management of neuroendocrine tumors compared to current FDA approved imaging modalities: a review of literature. . Am J Nucl Med Mol Imaging. 2014;4(5):426-34. 101. Kayani I, Bomanji JB, Groves A, Conway G, Gacinovic S, Win T, et al. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F- FDG. Cancer. 2008;112(11):2447-55. Epub 2008/04/03. 102. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-47. Epub 2008/12/23. 103. Fournier L, Ammari S, Thiam R, Cuenod CA. Imaging criteria for assessing tumour response: RECIST, mRECIST, Cheson. Diagn Interv Im. 2014;95(7- 8):689-703. Epub 2014/06/22. 104. Tirkes T, Hollar MA, Tann M, Kohli MD, Akisik F, Sandrasegaran K. Response criteria in oncologic imaging: Review of traditional and new criteria. Radiographics. 2013;33:1323-41. 105. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Seminars in liver disease. 2010;30(1):52-60. Epub 2010/02/23. 106. Hyun O, Lodge M, Wahl R. Practical PERCIST: A simplified guide to PET response criteria in solid tumors 1.0. Radiology. 2016;280(2):576-84. 107. Min SJ, Jang HJ, Kim JH. Comparison of the RECIST and PERCIST criteria in solid tumours: a pooled analysis and review. Oncotarget. 2016;7(19). 108. Hyun O, Lodge M, Wahl R. Practical PERCIST: a simplified guid to PET response criteria in solid tumors 1.0. Radiology. 2016;280(2):576-84. 109. Magistri P, Tarantino G, Ballarin R, Berretta M, Pecchi A, Ramacciato G, et al. The Evolving Role of Local Treatments for HCC in the Third Millennium. Anticancer research. 2017;37(2):389- 401. Epub 2017/02/10. 110. Bruix J, Reig M, Sherman M. Evidence- Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Ca rc i noma . Ga s t roen te ro l og y. 2016;150(4):835-53. Epub 2016/01/23. 111. Padia SA, Kwan SW, Roudsari B, Monsky WL, Coveler A, Harris WP. Superselective yttrium-90 radioembolization for hepatocellular carcinoma yields high response rates with minimal toxicity. J Vasc Interv Radiol. 2014;25(7):1067-73. Epub 2014/05/20.